



ODYSSEY
HEALTH

Developing Life-Saving Medical Products

OTC: ODYY




Forward Looking Statements

This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding Odyssey Health, Inc. f/ka Odyssey Group International (“Odyssey Health, Inc., Inc.” or the “Company”) future results of operations and financial position, including the financial results for the year ended July 31, 2022, financial targets, business strategy, plans and objectives for future operations, are forward-looking statements. The Company has based these forward-looking statements largely on its current estimates of its financial results and its current expectations and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy, short term and long-term business operations and objectives, and financial needs as of the date of this presentation. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in the Company’s filings with the Securities and Exchange Commission (the “SEC”). Moreover, the Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for Company management to predict all risks, nor can the Company assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, neither the Company nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason after the date of this presentation, to conform these statements to actual results or to changes in the Company’s expectations. The Company’s filings with the Securities and Exchange Commission are available to you and you should read the documents the Company has filed with the SEC for more complete information about the Company. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov.

The Company

- Odyssey Health Inc is a biomedical company focused on acquiring, developing and commercializing life-saving medical technologies and drugs that have superior clinical utility and a substantial market opportunity.
- The Company's team of experts and extensive relationships within the pharmaceutical and biotechnology industries allows Odyssey Health excellent idea and deal flow while maintaining stringent market and scientific due diligence and analysis.
- The Company's mission is creating clinically significant value and safety for the individual patient or organization while enhancing long term shareholder value.

Odyssey Subsidiaries



Neuro-Pharma Platform Technology: Intranasal Delivery

ONP-002 For Treating Concussion


ONP-002 is a First-in-Class Neurosteroid for the treatment of moderate to severe concussion.

ONP-001 For Niemann Pick Type-C (orphan)

ONP-001 is a First-in-Class Neurosteroid for the treatment of Niemann Pick Type-C Disease.


ONP-003 Nerve Gas Antidote

ONP- 003 is intended to be the first antidote delivered intra nasal directly to the Brain



Cardiac Device

- CardioMap is a non-invasive device that detects heart disease by digitally mapping the heart



*In development, not yet commercially available.

Medical Device

- The Save-A-Life (SAL) choking rescue device is currently in development. It is a patented design intended to be safe and easy to use for removing a lodged mass, or bolus, from the throat of a choking victim.



**Device concept; final production design may vary.*



ONP-002

Novel Compound for Treatment
of Concussion

About Concussion

Concussions, represent a significant unmet medical need

- > **5 Million** per year in the US, 69M worldwide
- Medical costs in the US is **\$20 Billion per year in US**, \$400B worldwide

Current standard of care is rest, analgesics for headache, anti-depressants

Repeat concussions can lead to early dementia and Chronic Traumatic Encephalopathy (CTE)

No FDA approved drug treatment exists for mTBI

75%

Likelihood of athlete head-injury recurrence

33%


Individuals over 65 that fall annually; 50% of deaths are from brain injury

25x

Frequency of military PTSD development post-concussion

About ONP-002

- New chemical entity: Proprietary Neurosteroid
- Proven in-vivo efficacy in animal concussion models through gene amplification of anti-inflammatories, anti-oxidants and efflux fluid channels
- Safety margin > 200-fold in animal toxicology studies
- Nasal administration drives drug into the brain in minutes
- IND-enabling studies complete
- Successfully completed a Phase 1 Human Clinical Trial
- Addressable market \$20B+ a year in the US alone





Mouth-to-Nose Administration

Intranasal (IN) administration allows rapid and direct accessibility to the brain

The Device

- requires patients to blow into the device which closes the soft palate eliminating the flow of drug to the lungs or esophagus
- Minimizes systemic exposure and side effects
- Enhances dispersion to the superior nasal roof for direct olfactory nerve brain delivery via a novel double tube airflow system
- Compact, 1X use lightweight-field deliverable




Superior depth of drug dispersion with double tube design

ONP-002 SUMMARY

ONP-002 – a First-in-Class Novel Neurosteroid for the Treatment of Concussion

- IP covers composition of matter, methods of preparation and use
- No competing products currently available
- Pre-clinical efficacy established
- No drug-related toxicity observed
- Initial formulation completed
- Unique Mouth-to-Nose applicator completed
- Phase I clinical trial completed
- Phase II clinical trials being planned. No dates at this time.
- Potential for other neurological indications





ONP-001

First-in-Class Neurosteroid for the
treatment of Niemann Pick Type-C
Disease.

About ONP-001

- ONP-001 binds to an intracellular steroid receptor. The ONP-001 receptor is an intracellular receptor found in neurons, glia and the endothelium of the blood brain-barrier.
- The induction of the ONP-001 receptor activates gene response elements leading to the transcription of P-Glycoprotein (PGP), which pumps cholesterol and lipid debris, out of the brain cells and the brain circulation.
- **ONP-001 Toxicology**
 - Acute and sub-acute dose ranging studies were executed in rats – intranasal and intravenous. No drug-related effects were noted in hematology, blood chemistry, or histopathology. IND-enabling studies are being scheduled. These studies will be followed by a Phase I safety trial.



ONP-003

Nasal Delivery of Nerve Gas Antidote.

Nerve Agents are a Constant Threat

EFFECTS:

- Kills brain cells, especially during prolonged exposure
- Can kill quickly by inducing respiratory failure and causing seizures
- Chemical warfare in the form of OrganoPhosphates is a constant threat world-wide.

INCIDENTS:

- Terrorist activity -- Germany WW2; Japan 1995; Syria 2016; UK 2018 ; Russia 2020; Ukraine concerns; current daily threat in Israel
- Accidental exposure -- Agriculture (insecticides); mosquito spraying

Nerve Gas Antidote: Solution/Treatment

- Intranasal delivered class of compounds called oximes
 - Generic antidote already on market in form of auto-injector
 - Antidote proven safety and efficacy – if properly used
 - Odyssey drug fast acting, delivered through nasal passage
 - Odyssey drug works by counteracting the cholinergic over-activation caused by organophosphate poisoning
 - Odyssey Drug is formulated in a dry powder and is stable at high and low temperatures.
 - Proprietary Nasal applicator has been tested successfully in a phase 1 human trial (concussion drug)

Nerve Gas Antidote: Problems to Solve

- Existing auto-injector is painful, unpleasant, and somewhat difficult to administer
- Easy to misdose causing pain, tissue necrosis, and lack of efficacy
 - Accidental finger sticks (or other parts of the body)
 - Incomplete injection
- Multidosing (up to 6 times in 24 hours) is often required
- Needle Phobia
- Disposal of “sharps” (needles) after use

Odyssey Improved Treatment


Existing Auto-Injector	Odyssey Nasal Delivery Product
Compound is effective in brain cells	Compound is effective in brain cells
Very little of compound is delivered to brain	High percentage of compound is delivered to brain
Compound takes several minutes to penetrate to brain	Compound takes only seconds to penetrate to brain
Delivery method breaks skin barrier	Delivery method does not break skin barrier
Painful, unpleasant delivery method	Painless delivery method
Easy to mis-dose causing pain or loss of efficacy	Easy to dose; no pain; high likelihood of efficacy

Other Indications For Nasal Delivery

Beyond Concussion, Odyssey

Plans to develop treatments of related brain injury and neuropsychiatric disorders with other novel neurosteroids (6) in its portfolio

- Major Depressive Disorder
- PTSD
- Dementia
- Generalized Anxiety
- Addiction
- ALS
- CTE



The image shows two white, rectangular CardioMap devices. The device in the foreground has a screen displaying a human silhouette with colored dots and lines representing a heart map. The device in the background has the CardioMap logo and a stylized ECG line. Several colored cables (purple, green, blue, yellow) are plugged into the top of the devices. The entire scene is set against a blue background with a semi-transparent overlay.

CardioMap System

Heart Monitoring and Screening Device


CardioMap System



Small, portable device for early detection of heart disease **more effective than traditional imaging services**




Regulatory pathway via 510(k) – small study to show equivalence to legacy EKG



Highly profitable razor-razor blade model with recurring cloud-based service



Multiple end-use markets: Hospitals, doctors' offices, rehab centers, sports medicine markets



*In development not commercially available

Advantages of CardioMap



CardioMap requires less training to use and analyze than EKGs



CardioMap is more sensitive than EKG's; captures low-level electrical signals that EKG's don't pick up




CardioMap can generate a 3D dispersion map of the heart (see images)




Physicians using CardioMap can give patients actionable information about heart health years in advance


CardioMap™ Images (Dispersion Maps)



Healthy Heart



Moderately Diseased Heart



Severely Diseased Heart

*In development not commercially available



- 1 Call 911
- 2 Remove Device from Dock
- 3 Tilt head back and lift Chin for access to air way
- 4 Insert Device into mouth Press Button until air way is cleared

Save-A-Life

Choking Rescue Device

In development, not commercially available



Save-A-Life (SAL) is a patented, single-action, instantaneous, handheld, mechanical, anti-choking device that creates a vacuum chamber in the mouth to dislodge throat obstructions **in a matter of seconds without harm**

Board of Directors

J. Michael Redmond, Chairman, CEO

30 years experience leading Medical Device companies, commercialized several class II and Class III devices. He has leadership experience at public and private companies including Abbott Labs, and KMC Systems.

John Gandolfo, Director

John has been CFO of several public and private medical device companies. He has raised over \$300M in IPOs and secondary offerings. John is Chair of the Audit Committee.

Jerome (Jerry) Casey, Director

Jerry has 30 years experience leading commercial teams at Abbott Laboratories and recently as President of Genzyme Diagnostics (Sekesui).

Ricky Richardson

Ricky has over 30 years of senior leadership experience in developing and manufacturing complex medical devices. Ricky has had senior leadership positions at Baxter and Danaher. He is a graduate of West Point.